

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 10162 - AMERISOURCEBERGEN / PARTS OF WALGREENS BOOTS ALLIANCE'S PHARMACEUTICAL BUSINESS

SECTION 1.2

Description of the concentration

On 7 April 2021, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 of 20 January 2004 on the control of concentrations between undertakings (the “**Merger Regulation**”), by which AmerisourceBergen Corporation (“**AmerisourceBergen**”) will acquire from Walgreens Boots Alliance (“**WBA**”) sole control within the meaning of Article 3(1)(b) of the Merger Regulation, over WBA’s Pharmaceutical Wholesale businesses in Algeria, Croatia, Czech Republic, Egypt, France, Lithuania, the Netherlands, Norway, Portugal, Romania, Spain, Turkey, the UAE and the UK and over the Retail Pharmacy International businesses in the Netherlands, Norway, and Lithuania.

AmerisourceBergen is a global pharmaceutical distribution and services company, with headquarters in the USA. It is a Delaware corporation with principal executive offices in Chesterbrook, Pennsylvania and is listed on the New York Stock Exchange.

WBA is a global retail and wholesale pharmacy business with headquarters in the USA and active in more than 25 countries. It is a Delaware corporation with principal executive offices in Deerfield, Illinois and is listed on the Nasdaq Stock Market.